Stay updated on SafetyEfficacy SGN-LIV1A+Pembrolizumab in TNBC Clinical Trial
Sign up to get notified when there's something new on the SafetyEfficacy SGN-LIV1A+Pembrolizumab in TNBC Clinical Trial page.

Latest updates to the SafetyEfficacy SGN-LIV1A+Pembrolizumab in TNBC Clinical Trial page
- Check2 days agoChange DetectedThe page now displays a 403 Forbidden error, replacing the study content with an access-denied screen. This indicates a site access issue rather than a change to the study information itself.SummaryDifference18%

- Check9 days agoChange DetectedRevision updated to v3.7.0 in the Study Documents section, replacing the previous v3.6.6. This reflects an updated set of trial documents.SummaryDifference0.0%

- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedThe page's revision label was updated to v3.6.6, replacing the previous v3.6.5. This indicates a minor maintenance update without changes to study details or patient-facing information.SummaryDifference0.0%

- Check30 days agoChange DetectedAdds a new funding identifier: '2017 ( U.S. NIH Grant/Contract )'. This expands the list of study identifiers with a funding source reference associated with the trial record.SummaryDifference0.0%

- Check44 days agoChange DetectedThe page revision was updated from v3.6.4 to v3.6.5, indicating a new deployment of the page template. No study content or visible information appears to have changed.SummaryDifference0.0%

- Check65 days agoChange DetectedThe page revision label changed from v3.6.3 to v3.6.4, indicating a backend update to the page. No study data, details, or actionable content were altered.SummaryDifference0.0%

Stay in the know with updates to SafetyEfficacy SGN-LIV1A+Pembrolizumab in TNBC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the SafetyEfficacy SGN-LIV1A+Pembrolizumab in TNBC Clinical Trial page.